| Home : Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) |
|
Feb 27
2019 |
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) |
|
WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The submission, which was initiated in December 2018, is... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/bayer-completes-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-investigational-drug-darolutamide-for-the-treatment-of-non-metastatic-castration-resistant-prostate-cancer-nmcrp |
| |
|
Related News
|
» Three in a row: Openlink wins Stevie Award for outstanding customer service
» Boeing, Vietjet Announce Order for 100 737 MAX Airplanes
|
